Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors
Vanessa Marensi, Karen Keeshan, David J. MacEwan
Topics & Concepts
Point mutationTyrosine kinaseCancer researchReceptor tyrosine kinaseMidostaurinROR1BiologyMutationFms-Like Tyrosine Kinase 3DasatinibProtein kinase domainPharmacologyMedicinePlatelet-derived growth factor receptorGeneticsReceptorMyeloid leukemiaGeneMutantGrowth factorAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research